• Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection | Science
    https://science.sciencemag.org/content/early/2021/01/06/science.abf4063.full

    #COVID-19 : De bonnes nouvelles sur le front de l’immunité | santé log
    https://www.santelog.com/actualites/covid-19-de-bonnes-nouvelles-sur-le-front-de-limmunite

    L’équipe de Jennifer M Dan du Center for Infectious Disease and Vaccine Research du La Jolla Institute for Immunology (Californie) a donc recruté plus de 180 hommes et femmes rétablis du COVID-19. 7% de ces participants avaient été hospitalisés mais la majorité avait développé une forme légère de la maladie. La plupart des participants ont fourni un échantillon de sang dès le 6è à 8è jour après l’apparition des symptômes. Les chercheurs ont pu suivre ainsi dans 254 échantillons au total, provenant de 188 cas de COVID-19, les anticorps, les cellules B (qui produisent les anticorps) et deux types de cellules T (qui tuent les cellules infectées). Ce suivi montre que :
    les anticorps, dont les anticorps dirigés contre les composants de la protéine de pointe, ne présentent que des baisses modestes 6 à 8 mois après l’apparition des symptômes ; les cellules T, ne montrent qu’une légère « décomposition » au fil du temps, les cellules B ont augmenté en nombre dans certains cas.

    Protective immunity against #SARS-CoV-2 could last eight months or more | EurekAlert! Science News
    https://www.eurekalert.org/pub_releases/2021-01/ljif-pia010621.php

    The team cautions that protective immunity does vary dramatically from person to person. In fact, the researchers saw a 100-fold range in the magnitude of immune memory. People with a weak immune memory may be vulnerable to a case of recurrent COVID-19 in the future, or they may be more likely to infect others.

    “There are some people that are way down at the bottom of how much immune memory they have, and maybe those people are a lot more susceptible to reinfection,” says Crotty.

    #immunité #anticorps

  • How modelling Covid has changed the way we think about epidemics | Coronavirus | The Guardian
    http://www.theguardian.com/commentisfree/2021/jan/04/covid-model-epidemic-collaboration-experiment
    https://i.guim.co.uk/img/media/00c5902c5c83fcee36c7e405c0e81c7810b62697/0_448_6720_4032/master/6720.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&overlay-ali

    Outbreak research should ideally be fast, reliable and publicly available. But the pressures of real-time Covid-19 analysis – which many academics have done in their spare time without dedicated funding – can force difficult choices. Should researchers prioritise updating scenarios for governments and health agencies, writing detailed papers describing their methods, or helping others adapt the models to answer different questions? These are not new problems, but the pandemic gave them new urgency. In the US, for example, the most comprehensive Covid-19 databases have been run by volunteers. The pandemic has flagged inefficient and unsustainable features of modelling and outbreak analysis, and illustrated that there is a clear need for change.
    Alongside coverage of specific modelling studies, mathematical concepts have also become part of everyday discussions. Whether talking about reproduction numbers, lags in data, or how vaccines might protect the non-vaccinated through “herd immunity”, journalists have started to think more deeply about epidemic dynamics. Prior to the outbreak, I never thought I’d end up fielding media requests to discuss a statistical parameter such as “K”, which quantifies the potential for super-spreading.Unfortunately, there have been challenges with coverage too. Some modelling results – particularly in the early stages of the pandemic – were widely misinterpreted, like the headlines in March suggesting half of the UK might have already been infected. Throughout summer and autumn, research groups also had to contend with media critics who misled the public with claims that the pandemic was over, dismissing warnings about the potential for a large second wave. Given the European epidemic waves to date, there can be little doubt that in the absence of control measures, Covid-19 would have been catastrophic for our health systems. Across the world, populations altered their behaviour in response to growing epidemics, but the extent of this unprecedented shift – and its effect on spread – was extremely hard to predict at the start of last year. Although infections such as Ebola and Sars have previously spurred behaviour change, Covid-19 triggered shutdowns of society on a scale unseen since the 1918 influenza pandemic.
    As well as modelling the spread of disease, researchers have had to track the dynamics of social behaviour. Because of modern digital footprints, they have been able to do this in more detail than ever, providing unique insights into how individuals and communities respond to outbreaks. These behavioural changes, whether driven by explicit government policies or local awareness of infection risk, have in turn had complex social, economic and health impacts. Untangling such effects will no doubt be the subject of research far into the future.Covid-19 has cemented a growing trend for research teams that work across multiple aspects of disease dynamics, from modelling and epidemiology to immunology and human behaviour. In the UK, researchers involved in modelling the disease have set up studies of social interactions and infection levels within communities, with these datasets then feeding back into new models.
    As well as interdisciplinary links, there have also been new international connections. Political responses to the pandemic have been country-specific, but throughout 2020, scientific insights – including datasets, modelling results and code – have been shared and built upon by teams across multiple continents. Past epidemics have brought mathematical tools to new audiences, but the scale of Covid-19 has resulted in epidemiological ideas being exchanged across disciplines and borders as never before. If sustained, such collaborations and networks could be hugely valuable in tackling other global epidemic challenges in future.The events of last year have altered the dynamics of many diseases, beyond Covid-19, as seen in the disappearance of certain seasonal infections or the disruption of vaccination programmes. Had the pandemic not happened, I would have spent much of 2020 abroad, setting up studies of influenza, Zika and dengue. When these projects eventually resume, will we see smaller outbreaks than before, or belated large epidemics? The pandemic has created a tragic “natural experiment”, a once-in-a-century jolt to disease ecosystems that could produce unexpected insights into immunity, social behaviour, seasonal effects and evolution. We’ve learned a lot about Covid-19 in the past 12 months, but there’s much more that modelling will help us discover in the coming years.

    #Covid-19#migrant#migration#sante#epidemiologie#modelisation#interactionsociales#reseau#immunité#pandemie

  • A Q&A about the new #coronavirus variant with the Fred Hutch scientist who’s been tracking its spread | The Seattle Times
    https://www.seattletimes.com/seattle-news/health/a-qa-about-the-new-coronavirus-variant-with-the-fred-hutch-scientist-w

    Q: You’ve said the new variant might be slightly less susceptible to vaccine-induced immunity, but that it isn’t different enough to completely foil existing vaccines. Why?

    A: The main reason I think that is because there’s a particular mutation in the U.K. variant that removes two different (portions) of the spike protein, and that tucks in a bit of protein that was sticking out and was an antibody target. So it removes that target for antibodies.

    And there was a study from a lab in Cambridge where they took serum from people who had recovered from #COVID and measured it against wild type virus and against viruses that have this deletion. And they saw that the antibodies of the recovered individuals neutralize the mutated virus significantly less than the wild type virus.

    If I had to hazard a guess, I believe we could see a modest reduction, like from 95% vaccine effectiveness to 85% or so, but I don’t think it would really severely inhibit the vaccine.

    [...]

    Q: What does the rapid emergence of this new variant suggest about the future? Are we going to eventually see strains that are resistant to all of vaccines?

    A: It was surprising to me, and I think, to most evolutionary virologists. The evolutionary mechanism definitely appears to be selection for more transmissibility. The virus evolves to more transmissible because that’s what evolution is selecting for.

    Most people haven’t yet been infected and don’t have immunity, but as we have more and more individuals with immunity from natural infection or vaccination, you do have more evolutionary pressure on the virus to evolve in ways that escape from that immunity.

    However, my main expectation here comes from what we know about seasonal coronavirus, which account for 30% of common colds. We can look at their evolution and they seem to infect people every three years or so and evolve at a slightly slower rate than influenza. That suggests to me a kind of flu-like pattern where you might need to update the vaccine every two or three years, and where evolving strains might be able to reinfect people on that sort of time scale as well.

    #mutation #variante #vaccin #immunité #vaccination

    • Tu lis le texte, et en particulier :

      Most people haven’t yet been infected and don’t have immunity, but as we have more and more individuals with immunity from natural infection or vaccination, you do have more evolutionary pressure on the virus to evolve in ways that escape from that immunity .

      ...et tu te demandes comment qualifier les cerveaux qui ont pu décider qu’une immunité collective pouvait être souhaitable ou envisageable...

      A quand un mouvement de la société civile pour réclamer une politique d’éradication du virus dès maintenant, et sans attendre une campagne improbable de vaccination ?

  • #COVID-19 neutralizing antibodies predict disease severity and survival : Cell
    https://www.cell.com/cell/abstract/S0092-8674(20)31685-8

    Les taux d’#anticorps, y compris neutralisant, sont d’autant plus élevés que la maladie est sévère et les décès sont nombreux ;

    Le taux de survie dépend de la puissance des anticorps neutralisant

    Pas d’#immunité croisée avec des coronavirus qui n’ont pas (encore) franchi la barrière d’espèce.

    We examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-RBD antibody levels.

    While anti-RBD IgG levels generally correlated with neutralization titer, quantitation of neutralization potency revealed that high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G, suggesting cross-protection from reinfection by either strain. However, SARS-CoV-2 sera generally lacked cross-neutralization to a highly-homologous pre-emergent bat coronavirus, WIV1-CoV, that has not yet crossed the species barrier. These results highlight the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics.

  • Discordant neutralizing antibody and T cell responses in asymptomatic and mild #SARS-CoV-2 infection | Science Immunology
    https://immunology.sciencemag.org/content/5/54/eabf3698.full

    ... the majority of individuals with mild or asymptomatic SARS-CoV-2 infection carry nAb complemented by multispecific T cell responses at 16-18 weeks after mild or asymptomatic SARS-CoV-2 infection.

    #immunité #anticorps

  • Defining the features and duration of antibody responses to #SARS-CoV-2 infection associated with disease severity and outcome | Science Immunology
    https://immunology.sciencemag.org/content/5/54/eabe0240.full

    COVID-19 severity affected by proportion of antibodies targeting crucial viral protein, study finds | News Center | Stanford Medicine
    http://med.stanford.edu/news/all-news/2020/12/study-identifies-difference-between-severe-and-mild-covid-19.html

    “Although previous studies have assessed the overall antibody response to infection, we compared the viral proteins targeted by these antibodies,” Boyd said. “We found that the severity of the illness correlates with the ratio of antibodies recognizing domains of the spike protein compared with other nonprotective viral targets. Those people with mild illness tended to have a higher proportion of anti-spike antibodies, and those who died from their disease had more antibodies that recognized other parts of the virus.”

    The researchers caution, however, that although the study identified trends among a group of patients, there is still substantial variability in the immune response mounted by individual patients, particularly those with severe disease. 

    “Antibody responses are not likely to be the sole determinant of someone’s outcome,” Boyd said. “Among people with severe disease, some die and some recover. Some of these patients mount a vigorous immune response, and others have a more moderate response. So, there are a lot of other things going on. There are also other branches of the immune system involved. It’s important to note that our results identify correlations but don’t prove causation.”

    #immunité #anticorps #covid-19

  • Rapid generation of durable B cell memory to #SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence | Science Immunology
    https://immunology.sciencemag.org/content/5/54/eabf8891.full

    [...] antibodies are detectable from approximately 6 days after PCR confirmation of infection, and those directed against spike receptor binding domain (RBD) show neutralizing capacity and hence, can prevent infection. However, the rapid decline of anti-SARS-CoV-2 serum IgG levels beyond 20 days post-diagnosis and the transient presence of circulating plasmablasts have led to questions about the longevity of immunity. In contrast, antigen-specific memory T cells and memory B (#Bmem) cells can be detected in convalescence. As these memory cells are programmed to respond rapidly upon subsequent antigen encounter, it is reasonable to hypothesize that these long-lived memory cells provide durable long-term immunity (4, 25). However, detailed insight into the nature and longevity of the Bmem cell compartment specific to SARS-CoV-2 is currently still unresolved.

    We extensively characterized the SARS-CoV-2-specific Bmem cell compartment using unique sets of fluorescently-labeled recombinant tetramers of the SARS-CoV-2 RBD and NCP antigens in combination with an extensive flow cytometry panel. The SARS-CoV-2-specific Bmem cells were quantified and characterized in 36 samples from 25 patients with COVID-19 or in convalescence. Circulating RBD- and NCP-specific Bmem cell subsets were detected early after infection and persisted over 242 days post-symptom onset. Early after infection, antigen-specific Bmem cells predominantly expressed IgM, followed over time by a predominance of IgG1. RBD-specific Bmem cell numbers were found to positively correlate with circulating TFH cell numbers suggesting prolonged germinal center (GC) activity. These analyses highlight that a decline in serum antibodies in convalescence may not reflect waning of immunity, but rather a contraction of the immune response with the development and persistence of B cell memory.

    #Covid-19 : une réponse immunitaire qui persiste au moins huit mois après les premiers symptômes
    https://www.lemonde.fr/sciences/article/2020/12/24/covid-19-une-reponse-immunitaire-qui-persiste-au-moins-huit-mois-apres-les-p

    Une étude australienne, publiée mardi 22 décembre dans la revue Science Immunology, offre un nouvel éclairage. Elle montre, chez 25 patients atteints du Covid-19 à des degrés variables puis convalescents, la présence d’une #immunité durable – au moins huit mois – qui mobilise des cellules B « mémoires », c’est-à-dire spécialisées contre ce virus.

    Ce résultat s’ajoute à ceux de quatre autres publications, qui toutes parviennent à une conclusion analogue. « Après une infection naturelle, ce virus peut déclencher la production de #cellules_mémoires spécifiques qui persistent un certain temps dans l’organisme. Cela laisse espérer que la #vaccination saura mobiliser ces mêmes cellules d’une manière au moins aussi efficace », estime Simon Fillatreau, professeur d’immunologie à l’Institut Necker - Enfants malades (AP-HP, Inserm, CNRS, Université de Paris).

  • Early Release - Antibody Responses 8 Months after Asymptomatic or Mild #SARS-CoV-2 Infection - Volume 27, Number 3—March 2021 - Emerging Infectious Diseases journal - CDC
    https://wwwnc.cdc.gov/eid/article/27/3/20-4543_article

    Waning humoral immunity in coronavirus disease patients has raised concern over usefulness of serologic testing. We investigated antibody responses of 58 persons 8 months after asymptomatic or mildly symptomatic infection with severe acute respiratory syndrome #coronavirus 2. For 3 of 4 immunoassays used, seropositivity rates were high (69.0%–91.4%).

    #anticorps #immunité

  • Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers | NEJM
    https://www.nejm.org/doi/full/10.1056/NEJMoa2034545

    Les anticorps développés après une infection par le #sars-cov2 sont protecteurs.

    BACKGROUND
    The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear.

    METHODS
    We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of asymptomatic and symptomatic staff at Oxford University Hospitals in the United Kingdom. Baseline antibody status was determined by anti-spike (primary analysis) and anti-nucleocapsid IgG assays, and staff members were followed for up to 31 weeks. We estimated the relative incidence of PCR-positive test results and new symptomatic infection according to antibody status, adjusting for age, participant-reported gender, and changes in incidence over time.

    RESULTS
    A total of 12,541 health care workers participated and had anti-spike IgG measured; 11,364 were followed up after negative antibody results and 1265 after positive results, including 88 in whom seroconversion occurred during follow-up. A total of 223 anti-spike–seronegative health care workers had a positive PCR test (1.09 per 10,000 days at risk), 100 during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike–seropositive health care workers had a positive PCR test (0.13 per 10,000 days at risk), and both workers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.03 to 0.44; P=0.002). There were no symptomatic infections in workers with anti-spike antibodies. Rate ratios were similar when the anti-nucleocapsid IgG assay was used alone or in combination with the anti-spike IgG assay to determine baseline status.

    CONCLUSIONS
    The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. (Funded by the U.K. Government Department of Health and Social Care and others.)

    #anticorps #immunité

  • #COVID-19 : premiers résultats d’une étude d’envergure menée grâce aux collaborateurs de l’Institut Curie sur la réponse immunitaire contre le SARS-CoV-2
    https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-premiers-resultats-etude-envergure-menee-grace-aux-collaborateurs-i

    Près de 1 850 collaborateurs volontaires de l’Institut Curie, représentatifs d’une population active francilienne, ont participé à Curie-O-SA, une étude sérologique lancée en mai dernier en collaboration avec l’Institut Pasteur. Avec un taux d’infection au virus SRAS-CoV-2 compris entre 11 et 16,6% (dont 21% de personnes asymptomatiques), ces résultats révèlent donc une forte prévalence de l’immunisation et des réponses immunitaires plutôt brèves. Dans 5% des cas, l’infection est prouvée par un test RT-PCR mais ne conduit pas à la production d’anticorps. A la Une du numéro de janvier 2021 de l’European Journal of Immunology, cette étude est prolongée pendant un an.

    [...]

    Par ailleurs, dans les sérums obtenus 4 à 8 semaines après le premier prélèvement, les analyses ont mis en évidence que la durée de demi-vie (c’est-à-dire le temps pour que la concentration d’anticorps diminue de 50%) des anticorps neutralisants n’était que de 4 semaines. Au cours d’études rétrospectives, ceci pourrait entraîner une sous-estimation de la prévalence réelle de l’infection. Néanmoins, la perte des anticorps spécifiques circulants ne signifie pas nécessairement la perte de protection. En effet la séroconversion s’accompagne d’une persistance des cellules T et B « mémoires » spécifiques prolongeant l’immunité des individus.

    #asymptomatiques #immunité

  • Fauci Predicts U.S. Could See Signs Of Herd Immunity By Late March Or Early April : Coronavirus Updates : NPR
    https://www.npr.org/sections/coronavirus-live-updates/2020/12/15/946714505/fauci-predicts-u-s-could-see-signs-of-herd-immunity-by-late-march-or-early-apri

    Grâce aux vaccins; avec un grand « si » cependant,

    Marc Lipsitch sur Twitter : “There is a big if to this. Works if the vaccines strongly block infection/infectiousness/transmission like measles and mumps vaccines. Won’t work if vax effects mainly on illness, with more modest effects on transmission, like pneumococcal and acellular pertussis vaccines.” / Twitter
    https://twitter.com/mlipsitch/status/1338921331564351489

    #sars-cov2 #covid-19 #vaccins #immunité_de_groupe

  • Encore rares, les #réinfections nous donnent des indices sur le fonctionnement de l’#immunité
    https://www.courrierinternational.com/article/covid-19-encore-rares-les-reinfections-nous-donnent-des-indic

    Pour qu’une réinfection soit avérée, le patient doit avoir effectué deux tests PCR (réaction en chaîne par polymérase) positifs, sans avoir présenté de symptôme pendant au moins un mois entre les deux. Chantal Reusken, virologue à l’Institut néerlandais de la santé publique et de l’environnement (RIVM), précise toutefois qu’un deuxième test peut également être positif soit parce que le patient a gardé dans les voies respiratoires des résidus d’ARN viral non réplicatif issus de la primo-infection, soit parce qu’il avait jugulé le virus sans jamais véritablement l’éliminer.

    C’est pourquoi, explique Paul Moss, hématologue à l’université de Birmingham, la plupart des revues médicales veulent voir entre la première et la deuxième infection deux séquences virales à part entière, très différentes l’une de l’autre. “La barre est très haute, dit-il. Dans bien des cas, il n’y a même pas la moindre trace de matériel génétique [du virus].”

    Et même si cet ARN est présent, de nombreux laboratoires n’ont ni assez de temps ni assez d’argent pour le détecter. De ce fait, le nombre de réinfections attestées par des séquences génétiques reste très inférieur au nombre de suspicions de réinfection.

    #paywall

    Reinfections, still rare, provide clues on immunity | Science
    https://science.sciencemag.org/content/370/6519/895.full

    #covid-19

  • Decline in #SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020 | MMWR
    https://www.cdc.gov/mmwr/volumes/69/wr/mm6947a2.htm

    Deuxième dosage des anticorps 60 jours après la mise en evidence d’une séropositivité (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470460) chez des sujets qui avaient développé une forme légère de la maladie.

    Summary

    What is already known about this topic?

    Most persons develop virus-specific antibodies to SARS-CoV-2 after infection; however, the timeline of antibody decline over time is uncertain.

    What is added by this report?

    Among 156 frontline health care personnel who had positive SARS-CoV-2 antibody test results in spring 2020, 94% experienced a decline at repeat testing approximately 60 days later, and 28% seroreverted to below the threshold of positivity. Participants with higher initial antibody responses were more likely to have antibodies detected at the follow-up test than were those who had a lower initial antibody response.

    What are the implications for public health practice?

    SARS-CoV-2 antibodies decline over weeks following acute infection. Negative SARS-CoV-2 serologic results do not exclude previous infection , which has significant impacts on how serologic studies are interpreted.

    [...]

    ... misclassification of antibody status was possible; however, this was considered to be unlikely because of the high sensitivity and specificity of the ELISA.

    These antibody declines might not equate to loss of protective immunity or increased risk for #reinfection; this was not assessed in this study.

    [...]

    Whether decay in these antibodies increases risk for reinfection and disease remains unanswered.

    #anticorps #immunité

  • #SARS-CoV-2 seroprevalence and antibody kinetics among health care workers in a Spanish hospital after three months of follow-up | The Journal of Infectious Diseases | Oxford Academic
    https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa696/5974123

    #COVID-19 : L’infection reste détectable [au moins] 3 mois | santé log
    https://www.santelog.com/actualites/covid-19-linfection-reste-detectable-3-mois

    à 3 mois,

    [...]

    ... 97% maintiennent des taux détectables d’IgG. En fait, les niveaux d’IgG chez certains des participants ont même augmenté par rapport à la première analyse. Ce n’est pas la première étude à montrer que les niveaux d’#anticorps immunoglobuline G restent élevés chez les patients au moins 2 mois après l’infection.

    [...]

    Les personnes infectées sont-elles protégées contre la réinfection et un nouveau développement de la maladie ? La question se pose toujours.
    L’étude de cohorte se poursuit afin d’évaluer l’évolution de la #séroprévalence dans ce groupe à haut risque, la durée des anticorps détectables, y compris plusieurs isotypes et sous-classes de plusieurs antigènes, et leur rôle dans la protection contre la maladie et la réinfection.

    #immunité

  • Early Release - Cellular Immunity in #COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG - Volume 27, Number 1—January 2021 - Emerging Infectious Diseases journal - CDC
    https://wwwnc.cdc.gov/eid/article/27/1/20-3772_article

    La plupart des sujets PCR #SARS-CoV-2 positifs qui ne développent pas d’anticorps (60 jours après l’installation des symptômes), développent une #immunité_cellulaire (tout comme les sujets qui fabriquent des #anticorps)

    We investigated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among a group of convalescent, potential blood donors in Germany who had PCR-confirmed SARS-CoV-2 infection. Sixty days after onset of symptoms, 13/78 (17%) study participants had borderline or negative results to an ELISA detecting IgG against the S1 protein of SARS-CoV-2. We analyzed participants with PCR-confirmed infection who had strong antibody responses (ratio >3) as positive controls and participants without symptoms of SARS-CoV-2 infection and without household contact with infected patients as negative controls. Using interferon-γ ELISpot, we observed that 78% of PCR-positive volunteers with undetectable antibodies showed T cell immunity against SARS-CoV-2. We observed a similar frequency (80%) of T-cell immunity in convalescent donors with strong antibody responses but did not detect immunity in negative controls. We concluded that, in convalescent patients with undetectable SARS-CoV-2 IgG, immunity may be mediated through T cells.

    [...]

    According to our data in volunteers with confirmed SARS-CoV-2 infection, it could be speculated that the majority of persons with undetectable systemic IgG may presumably be protected by specific T-cell immunity, which would be good news for the control of the pandemic.

    #immunité

  • (Les enseignements de l’article sont plus larges que ne le laisse supposer le titre)

    #Covid-19 : la durée de la réponse immunitaire neutralisante plus longue chez les femmes que chez les hommes | Institut Pasteur
    https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-duree-reponse-immunitaire-neutralisante-plus-longue-femmes-que-homm

    L’évolution de la réponse #anticorps contre le #SARS-CoV-2 chez les individus infectés reste mal caractérisée. Pour tenter d’élucider ces questions sur l’évolution de la réponse immunitaire, des équipes du CHU de Strasbourg et de l’Institut Pasteur ont suivi 308 membres du personnel hospitalier qui ont développé des formes légères de la COVID-19 ne nécessitant pas de prise en charge hospitalière.

    La présence d’anticorps anti SARS-CoV-2 a été mesurée par trois techniques différentes : deux ciblant la protéine Spike (S) du virus, et un test ciblant sa nucléocapside (N). L’activité neutralisante de ces différents anticorps a aussi été mesurée avec un test mesurant la capacité à bloquer le virus.

    Ces mesures ont révélé que les hommes de plus de 50 ans, ou ceux ayant un indice de masse corporelle (IMC) supérieure à 25, présentent des niveaux d’anticorps plus élevés à un mois après le début des symptômes, par rapport au reste des individus testés.

    Entre 3 et 6 mois, les anticorps anti-S et les anticorps neutralisants persistent respectivement chez 99% et 84% des individus. En revanche, les anticorps anti-N ne sont trouvés que chez 59% des individus. Ceci montre que selon le test utilisé, la #séroprévalence SARS-CoV-2 peut être sous-estimée .

    De plus, les chercheurs ont montré que le taux des anticorps anti-S et celui des anticorps neutralisants, entre 3 à 6 mois, baissent plus rapidement chez les hommes que chez les femmes, indépendamment de l’âge et de l’IMC. Ce résultat suggère que la durée d’immunité contre le SARS-CoV-2 serait plus longue chez les femmes que chez les hommes.

    [...]

    La prochaine étape sera d’étudier chez cette même cohorte l’autre aspect de la réponse immunitaire, la réponse cellulaire T, pour obtenir une vision globale sur la réponse immunitaire anti-SARS-CoV-2 et son évolution dans les formes légères de la COVID-19 », Pr. Samira Fafi-Kremer, directrice de l’Institut de Virologie de Strasbourg.

    #immunité #sérologie

  • Immunity to the #Coronavirus May Last Years, New Data Hint - The New York Times
    https://www.nytimes.com/2020/11/17/health/coronavirus-immunity.html

    The research, published online, has not been peer-reviewed nor published in a scientific journal. But it is the most comprehensive and long-ranging study of immune memory to the coronavirus to date.

    “That amount of memory would likely prevent the vast majority of people from getting hospitalized disease, severe disease, for many years,” said Shane Crotty, a virologist at the La Jolla Institute of Immunology who co-led the new study.

    The findings are likely to come as a relief to experts worried that immunity to the virus might be short-lived, and that vaccines might have to be administered repeatedly to keep the pandemic under control.

    [..,]

    A study published last week also found that people who have recovered from #Covid-19 have powerful and protective killer immune cells even when antibodies are not detectable .

    These studies “are all by and large painting the same picture, which is that once you get past those first few critical weeks, the rest of the response looks pretty conventional,” said Deepta Bhattacharya, an immunologist at the University of Arizona.

    Akiko Iwasaki, an immunologist at Yale University, said she was not surprised that the body mounts a long-lasting response because “that’s what is supposed to happen.” Still, she was heartened by the research: “This is exciting news.”

    Sources :

    Immunological memory to #SARS-CoV-2 assessed for greater than six months after infection | bioRxiv
    https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1

    Characterization of pre-existing and induced SARS-CoV-2-specific CD8 + T cells | Nature Medicine
    https://www.nature.com/articles/s41591-020-01143-2

    #immunité_cellulaire #immunité

  • Antibody evolution may predict #COVID-19 outcomes | EurekAlert ! Science News
    https://www.eurekalert.org/pub_releases/2020-11/mgh-aem111320.php

    For COVID-19, the difference between surviving and not surviving severe disease may be due to the quality, not the quantity, of the patients’ antibody development and response, suggests a new Cell paper published by Galit Alter, PhD, a member of the Ragon Institute of MGH, MIT and Harvard.

    [...]

    Compared to survivors, patients who passed from COVID-19 had antibodies that never fully developed the ability to strongly bind to Fc-receptors and therefore may not have been able to fully trigger immune killing activity.

    Alter’s group, led by Tomer Zohar, Carolin Loos, Stephanie Fischinger, and Caroline Atyeo, PhD, also found that survivors’ immune systems could recognize and target an area of the SARS-CoV-2 spike protein known as the S2-domain. The S2 domain is found in other coronaviruses that infect humans, so patients whose antibodies can target it may have pre-existing immunity to the S2 domain because of exposure to other, common coronaviruses.

    Patients with antibodies that can recognize S2 domains on different coronaviruses may be able to use this pre-existing immunity to generate killer antibodies faster and sooner following SARS-CoV-2 infection.

    “If we can further understand the importance of cross-coronavirus immunity,” says Zohar, “researchers may be able to design vaccines able to counteract a much broader range of coronaviruses.”

    #immunité #immunité_croisée

  • Assessment of #SARS-CoV-2 RNA Test Results Among Patients Who Recovered From COVID-19 With Prior Negative Results | Infectious Diseases | JAMA Internal Medicine | JAMA Network
    https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2773053

    Parmi 176 personnes guéries du #COVID-19, le PCR est redevenu positif après un délai moyen de 48.6 jours chez 32 (18%), alors qu’ils étaient tous sauf 1 restés asymptomatiques.

    Une activité de réplication a été recherchée chez ces « re-positifs » et n’a été mise en évidence que chez la personne symptomatique (16 jours après la guérison, 39 jours après le diagnostic initial).

    Discussion

    Similar to that reported elsewhere,2 18% of patients with COVID-19 in our institution became RT-PCR positive for SARS-CoV-2 RNA after clinical recovery and previous negative results.5 As positivity in the patients was suggestive, but not necessarily a reflection, of viral carriage, we used replicative SARS-CoV-2 RNA detection as a proxy for virus replication in culture.4

    Only 1 of 32 patients retesting positive had replicating virus in the NOS sample, suggesting either recurrent infection or reinfection, which is impossible to separate because no whole-genome sequencing and phylogenetic analyses were performed.3 The patient retested positive 16 days after COVID-19 recovery (ie, 39 days from COVID-19 diagnosis) and was symptomatic. The patient was an older adult with hypertension, diabetes, and cardiovascular disease but no evidence of close contacts with people with SARS-CoV-2 infection or persons who became RT-PCR positive. In the 31 remaining patients (who were asymptomatic), their positive result likely represented either recurrent or resolving infection, but in either case, they were unlikely to be infectious. The limitations of our study are the lack of data from viral cultures or whole-genome sequencing analysis and the small sample size.

    Conclusions

    This study highlights that many patients who recovered from COVID-19 may be still positive (albeit at lower levels) for SARS-CoV-2 RNA, but only a minority of the patients may carry a replicating SARS-CoV-2 in the respiratory tract. Further studies are needed to verify whether such patients can transmit the virus.

  • Herd immunity policy in German schools leads to explosion of coronavirus infections - World Socialist Web Site
    https://www.wsws.org/en/articles/2020/11/14/coro-n14.html
    https://www.wsws.org/asset/a40fb223-abf1-42be-9461-b83776dba716?rendition=image1280

    The number of people infected with coronavirus in Germany continues to rise steadily, with more people being taken into hospital, intensive care units and needing ventilators every day. On Friday, the Robert Koch Institute (RKI) registered 23,542 COVID-19 infections in 24 hours, an all-time high. Over 600 new patients were admitted to intensive care units and another 218 patients died from the virus.

    This week, pharmaceutical companies Pfizer and BioNTech announced news of a possible breakthrough in the search for a COVID-19 vaccine. Other clinical studies also confirm that it may soon be technically possible to provide the world’s population with a vaccine against Sars-CoV-2. A possible end to the pandemic is thus within reach. And yet capitalist politicians refuse to do everything possible to protect the population.

    #allemagne #imunité_collective

  • #Covid-19 : de nouvelles données sur l´#immunité
    https://www.futura-sciences.com/sante/actualites/coronavirus-covid-19-nouvelles-donnees-immunite-83472

    La question de l’immunité engendrée par le coronavirus #SARS-CoV-2 défie encore les scientifiques. Deux médecins, l’un de l’université Emory d’Atlanta, l’autre du Fred Hutchinson Cancer Research Center de Seattle, se sont plongés dans la littérature scientifique récente pour essayer de faire émerger un schéma général de l’immunité adaptative déclenchée par le SARS-CoV-2 et son évolution au cours des semaines. Leur point de vue a été partagé par Jama.

    Le schéma général de la réponse immunitaire adaptative anti-SARS-CoV-2. La courbe du haut concerne les lymphocytes T et celle du bas les lymphocytes B et les anticorps. © David S. Stephen et Juliana Mc Elrath, Jama

    Source : COVID-19 and the Path to Immunity | Allergy and Clinical Immunology | JAMA | JAMA Network
    https://jamanetwork.com/journals/jama/fullarticle/2770758

    #immunité_cellulaire #immunité_humorale
    #immunité_adaptative

  • #SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers | medRxiv
    https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v1

    Results T cells responsive to the spike (S), nuclear (N) and membrane proteins (M) dominated the responses measured. Using the sum of the spots (responsive cells within each well of 250,000 peripheral blood mononuclear cells) for S, N and M antigens minus the control, the 2,672 unselected participants were divided into those with higher responses (n=669, 25.4%; median 30 spots (IQR 18,54)) and those with low responses (n=2016, 76.7%, median 3 (IQR 1,6)), the cutoff we derived being 12 spots. Of the participants with higher T cell responses, 367 (53%) had detectable antibodies against the N or S proteins. During a median of 118 days follow-up, 20 participants with lower T cell responses developed COVID-19, compared with none in the population with high T cell responses (log-rank test, p=6×10−3).

    #immunité_cellulaire

  • Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection | bioRxiv
    https://www.biorxiv.org/content/10.1101/2020.11.01.362319v1

    Les moyens pour mettre en évidence l’#immunité_cellulaire étant beaucoup plus complexes que ceux utilisés pour l’immunité humorale, les études qui lui sont dévolues sont beaucoup plus rares.

    Comme pour les anticorps, les taux sont plus élevés dans les formes sévères,

    In conclusion, our data are reassuring that functional #SARS-CoV-2 specific T-cell responses are retained at six months following infection although the magnitude of this response is related to the clinical features of primary infection.

    #preprint #immunité